News

GryNumber is one of the leading healthcare consultancy and distribution companies in the region, with many years of experience. The agreement covers the distribution of Lojuxta across Austria,

The approval is for the treatment of adult patients in whom the condition is inadequately controlled even after being subjected to high-dose inhaled corticosteroids and long-acting beta-agonists. The

The trial (known as BGBC004) is designed to test the hypothesis that selective AXL inhibition with the once-daily oral small molecule bemcentinib may reverse and prevent resistance to

The goal of the partnership is to design innovative studies that have the potential to address cancers with high unmet need. The initial trial under consideration between Inovio

The 5-ht6 antagonist failed to meet its primary efficacy endpoints in the phase 2b HEADWAY and pilot phase 2 Gait and Balance studies. In the HEADWAY trial, intepirdine

UK Biobank aims to enhance the prevention, diagnosis and treatment of a range of severe illnesses including heart diseases, stroke, diabetes, cancer, arthritis, osteoporosis, eye disorders, depression and forms

The role of BRUDAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve the TLANDO New Drug Application (“NDA”) is anticipated

Baxter will assume other expenses, including contingent liabilities associated with PREVELEAK. Baxter is a global medical products company that is committed to advancing surgical innovation with a variety

This Breakthrough Therapy Designation is supported by positive Phase 2b results previously announced in September 2017,11 and marks 13 Breakthrough Therapy Designations granted to AbbVie's investigational treatments since